---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-116280"
form_type: "8-K"
ticker: "BRNS"
cik: "0001828185"
company_name: "Barinthus Biotherapeutics plc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:31:35.023886+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Barinthus Bio reports Q3 net loss $14.1M; cash $160.3M, runway to Q2 2025

## Summary
- Net loss of $14.1M ($0.37 per share) in Q3 2023, compared to $23.8M loss ($0.62 per share) in Q2 2023.
- Cash and cash equivalents $160.3M as of Sep 30, 2023; expects runway into Q2 2025.
- R&D expenses $15.1M in Q3, up from $13.5M in Q2, driven by VTP-300 HBV and VTP-850 trials.
- Upcoming milestones: interim data from two Phase 2 HBV trials at AASLD Nov 2023; Australia submission for VTP-1000 (celiac).
- Company changed name from Vaccitech to Barinthus Biotherapeutics in Nov 2023.

## SEC filing metadata
- accession: 0001104659-23-116280
- form_type: 8-K
- ticker: BRNS
- cik: 0001828185
- company_name: Barinthus Biotherapeutics plc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828185/000110465923116280/0001104659-23-116280-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828185/000110465923116280/tm2330270d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-116280
- JSON: https://secwatch.observer/filing/0001104659-23-116280.json
- Plain text: https://secwatch.observer/filing/0001104659-23-116280.txt

## Key facts
- Earnings Releases
  Barinthus Biotherapeutics plc. reported third quarter of 2023 results: net income $14.1 million, EPS $0.37 per share on both basic and fully diluted bases.
  - Period: third quarter of 2023
  - Net income: $14.1 million
  - EPS: $0.37 per share on both basic and fully diluted bases
  - Result: reported results
  source text: For the third quarter of 2023, the Company generated a net loss attributable to its shareholders of $14.1 million, or $0.37 per share on both basic and fully diluted bases, compared to a net loss attributable to shareholders of $23.8 million, or $0.62 per share on both basic and fully diluted bases in the second quarter of 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1828185/000110465923116280/0001104659-23-116280-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.